Ernexa Therapeutics Inc (ERNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -12,176 | -6,647 | -21,668 | -15,515 | -9,924 |
| Depreciation Amortization | 2,038 | 986 | 1,426 | 694 | 125 |
| Accounts receivable | 197 | 74 | 527 | -825 | -33 |
| Other Working Capital | 3,154 | 980 | -1,941 | -2,472 | -1,514 |
| Other Operating Activity | 781 | 860 | 1,248 | 2,371 | 1,425 |
| Operating Cash Flow | $-6,006 | $-3,747 | $-20,408 | $-15,747 | $-9,921 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -346 | -97 | -19 | N/A | N/A |
| Investing Cash Flow | $-346 | $-97 | $-19 | $N/A | $0 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 1,405 | 1,405 | 18,003 | 8,715 | N/A |
| Debt Repayment | N/A | N/A | -1,500 | N/A | N/A |
| Common Stock Issued | N/A | N/A | 320 | 320 | 320 |
| Dividend Paid | -8 | N/A | -16 | -8 | -8 |
| Other Financing Activity | -34 | -20 | -251 | -175 | 0 |
| Financing Cash Flow | $1,363 | $1,385 | $16,556 | $8,852 | $312 |
| Beginning Cash Position | 11,670 | 11,670 | 15,541 | 15,541 | 15,541 |
| End Cash Position | 6,681 | 9,211 | 11,670 | 8,646 | 5,932 |
| Net Cash Flow | $-4,989 | $-2,459 | $-3,871 | $-6,895 | $-9,609 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,006 | -3,747 | -20,408 | -15,747 | -9,921 |
| Capital Expenditure | -350 | -101 | -19 | N/A | N/A |
| Free Cash Flow | -6,356 | -3,848 | -20,427 | -15,747 | -9,921 |